The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy
Patient with locally advanced or post-operative ENT cancer with high risk of recurrence
Patient ≥ 18 years
Absence of prior chemotherapy or radiotherapy
Patient eligible for chemotherapy with cisplatin according to the standard regimen: radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks associated with chemotherapy with cisplatin 100 mg/m2 every 3 weeks (i.e. at week 1, 4 and 7)
Tinnitus grade ≥ 2 according to the SOMA-LENT scale
Patient fitted for hearing disorders
Significant cognitive disorders that may compromise the performance of the various assessments
Patients treated with weekly cisplatin